A Phase II, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of DIsulfiram and Copper Gluconate in Recurrent Glioblastoma

Trial Profile

A Phase II, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of DIsulfiram and Copper Gluconate in Recurrent Glioblastoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Copper-gluconate/disulfiram (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Sponsors Cantex Pharmaceuticals
  • Most Recent Events

    • 01 May 2017 Top-line results of the endpoints evaluated in this trial are expected in late 2017 and during the first half of 2018, according to a Cantex Pharmaceuticals media release.
    • 01 May 2017 According to a Cantex Pharmaceuticals media release, dosing has been initiated in this trial.
    • 04 Apr 2017 Topline results from this trial are expected in the second half of 2017, according to a Cantex Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top